drugset / Trial / NCT00394563
A Phase II Study Looking at Moderate to Severe Osteoarthritis Knee Pain
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to look at the effects of RN624 on moderate to severe knee pain due to osteoarthritis. This study will look at the safety and pain relieving effects of RN624 compared to placebo over a 4 month period.
Timeline
- Start
- 2006-03
- Primary completion
- 2007-10
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tanezumab | Monoclonal antibody | 10 ug/kg | — |
| Subject | Tanezumab | Monoclonal antibody | 25 ug/kg | — |
| Subject | Tanezumab | Monoclonal antibody | 50 ug/kg | — |
| Subject | Tanezumab | Monoclonal antibody | 100 ug/kg | — |
| Subject | Tanezumab | Monoclonal antibody | 200 ug/kg | — |